Login to Your Account

Agennix Restructures, Cuts Staff in Wake of Talactoferrin Bomb

By Cormac Sheridan
Staff Writer

Wednesday, August 29, 2012
Agennix AG is cutting more than half of its work force and shutting down a small drug development facility in Houston, in the wake of the recent failure of its lead drug talactoferrin in a Phase III trial in non-small-cell lung carcinoma (NSCLC).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription